Sinobioway Medicine(SZ:002581) 2 1 Shi Ji Jing Ji Bao Dao·2025-04-24 14:11Core Viewpoint - Unimed Pharmaceutical announced a significant impact on its operations due to the suspension of production and sales at its subsidiary Tianjin Unimed Biopharmaceutical Co., Ltd. by the Tianjin Drug Administration, which may lead to further risk warnings if production does not resume within three months [1] Group 1: Company Operations - Tianjin Unimed is a key subsidiary of Unimed Pharmaceutical, primarily engaged in the production and sales of interferon drugs [1] - The company reported that Tianjin Unimed generated revenue of 217 million yuan in 2024, accounting for 60.09% of Unimed's total revenue, and contributed a net loss of 14.0037 million yuan, representing 9.8% of the consolidated net profit [1] - The suspension was due to non-compliance with the Good Manufacturing Practice (GMP) requirements as assessed during an inspection by the Tianjin Drug Administration [1] Group 2: Financial Performance - Unimed Pharmaceutical's 2024 annual report indicated a revenue of 360 million yuan, a year-on-year decrease of 16.14%, and a net loss of 137 million yuan, with losses widening by 58.70% compared to the previous year [2] Group 3: Market Reaction - Following the announcement, Unimed Pharmaceutical's stock price fell by 2.49%, closing at 8.24 yuan per share, with a total market capitalization of 5.436 billion yuan [3]